EAN News Network : Episode 6

Clinical Pearls for MS Management in Everyday Practice


Dr Macaron shares her interpretation of the data and importance of individualizing treatment for patients with multiple sclerosis.

Gabrielle Macaron, MD: This study shows that ozanimod treatment is associated with positive outcomes on clinical and regenological measures of disease activity. This was seen in patients who were treatment naïve or in patients who were already on another disease-modifying therapy at baseline. This effect was maintained over the duration of the study period, which was 4 years. The clinical implication of this result is that patients with relapsing or remitting MS [multiple sclerosis] can benefit from ozanimod as a first- or second-line therapy. It’s important, however, to have a direct and long-term comparison of outcomes between these groups to see if treatment-naïve patients will benefit more in the long term. This would be in line with the first- line high-efficacy treatment approach in MS, which has been increasingly used in practice in the past few years.

In summary, significant recent data show that early treatment with a high-efficacy medication seems to be a good approach for many of our patients with MS, and delaying treatments is associated with poor outcomes in the long term, based on several recent studies evaluating this. My main advice is for every patient to always individualize treatment decisions based on the course and characteristics of the disease, such as the MRI lesion burden, the severity, and the frequency of relapses. It’s also based on patient characteristics: their age, family plans, and comorbidities but also their preferences. It takes into account the dynamic and continuous process of MS pathology throughout the life of a patient. Especially when we interpret data from randomized control trials, which aren’t necessarily generalizable to all our patients. When we pick a treatment according to randomized control trials, always think of the individual patient and how generalizable the data are and applicable they are and to our patients.

Transcript edited for clarity

Related Videos
 Bruce Cree, MD, PhD, MAS, FAAN
Valerie J. Block, PT, DPTSc
Patricia K. Coyle, MD
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
Kathy Zackowski, PhD, OTR
© 2024 MJH Life Sciences

All rights reserved.